source
- Bausch + Lomb appoints board chair Thomas Appio as interim CEO after Brent Saunders departsBausch + Lomb announced that board chair Thomas Appio will serve as interim chief executive, taking over immediately from Brent Saunders, who is leaving the role. Appio, who has held several leade…
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.Fierce Biotech · 10d ago↗ source
- Novartis licenses Abogen’s mRNA CD19×CD3 engager in $575M upfront deal